Advaxis, Inc. and the University of Pennsylvania (“UPenn”) signed a patent amendment agreement (the “Second Amendment Agreement”) allowing Advaxis to acquire exclusive licenses for an additional twenty-seven (27) patents related to the company’s proprietary Listeria vaccine technology.
“This second amendment to our current patent licensing agreement is quite important for the development of Advaxis’ platform technology,” commented Advaxis Chairman/CEO Thomas A. Moore. “Although we are currently in a solid position regarding our technology,IP position and exclusive licensee status with UPenn, this second amendment ensures our continued growth. Our patent portfolio is comprehensive and defendable as evidenced in our successful patent defense in European patent court last year.“
About the UPenn-Advaxis Licensing Agreement
This licensing is part of the company’s 20-year exclusive worldwide license agreement with UPenn. It covers patents that expire as late as 2023. As per the terms of the agreement, Advaxis is required to reimburse UPenn a portion of the associated licensing fees and all legal expenses. In addition, Advaxis provides milestone payments upon achievement of Phase III Trials, regulatory approval and commercialization. UPenn also receives a 1.5% royalty fee.
